Daniel Lin, MD
Urology · Seattle, WANPI 1548356306
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,780 of the $38,771 with a category attached, or 94.9%. 7 manufacturers reported payments, led by Bayer at 36.6% of the total. Reporting peaked in 2019 at $12,145 and has fallen 75.0% since, to $3,038 in 2024. Among urology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 38 payments — averaging $1020.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$14K
- Janssen Scientific Affairs, LLC$7K
- Astrazeneca UK Limited$7K
- Ferring Pharmaceuticals Inc.$6K
- Progenics Pharmaceuticals, Inc.$3K
- Johnson & Johnson$1K
- plus $38 from 1 others
Across 6 payments — averaging $394.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$2K
What the payments were for
- Consulting fees$36,78095%
- Travel & lodging$1,2713%
- Food & beverage$7212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 14 | $14,174 |
| Janssen Scientific Affairs, LLC | 8 | $7,389 |
| Astrazeneca UK Limited | 8 | $7,262 |
| Ferring Pharmaceuticals Inc. | 5 | $5,818 |
| Progenics Pharmaceuticals, Inc. | 1 | $3,000 |
| Johnson & Johnson | 1 | $1,090 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $38 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nubeqa$8,490
- IMFINZI$7,262
- Non-Covered$5,426
- PYLARIFY$3,000
- Erleada$2,913
How this compares
$38,771 in reported general payments places this provider in the 90th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 92 | $2,524 |
| Finasteride | 36 | $683 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $216 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 11 | $148 |
| Ciprofloxacin Hcl | 46 | $85 |
Paid to pharmacies, not to this prescriber.
Other urology in Seattle
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Vi NguyenSeattle$53K
- Rogerio HuangSeattle$45K
- Cristopher GarlitzSeattle$45K
- Sarah PsutkaSeattle$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.